Prosthetic heart valve with surface modification

• US 6,764,509 B2
• Filed: 12/21/2000
• Issued: 07/20/2004
• Est. Priority Date: 09/06/1996
• Status: Expired due to Term

• Current Assignee: Corcym SRL (LivaNova Plc)
• Original Assignee: Carbomedics Inc. (Snia SpA)
• Inventors: Chinn, Joseph Andrew, Frautschi, Jack R., Phillips, Richard E. Jr.
• Primary Examiner(s): Isabella, David J.
• Application Number:
  US09/746,979
• Publication Number:
  US 20010025196A1
• Time in Patent Office: 1,307 Days
• Field of Search: 623/11.11, 623/2.1, 623/2.12, 623/2.42, 623/23.76, 623/23.71, 623/23.72, 623/23.58, 623/23.59
• US Class Current: 623/2.12
• CPC Class Codes: A61F 2/2412 with soft flexible valve members, e.g. tissue valves shaped like natural valves check valves with flexible valve members in general F16K15/14
• CPC Class Codes: A61L 27/28 Materials for coating prostheses
• CPC Class Codes: A61L 27/34 Macromolecular materials

Abstract

Biocompatible prostheses, specifically, biocompatible heart valves, are described having incorporated therein an effective amount of coating applied thereto to render the valve resistant to in vivo pathologic thrombus formation and in vivo pathologic mineralization. Preferably, the coating is derived from a precursor having the formula:

X—Y—Z

wherein X is a chemically reactive group capable, upon activation, of bonding to the surface of the heart valve; Y is either null or a relatively inert skeletal moiety resistant to cleavage in aqueous physiological fluids; and Z is a functionally active moiety or a biocompatible agent.

Claims

1. A biocompatible heart valve comprising:

a stent defining a blood flow path; and

a plurality of polymeric leaflets having a surface coating to provide resistance to in vivo pathologic thrombus formation and in vivo pathologic mineralization, wherein the surface coating comprises a precursor of the formula;

2. A biocompatible heart valve comprising:

a stent defining a blood flow path; and

a plurality of polymeric leaflets having a surface coating to provide resistance to in vivo pathologic thrombus formation and in vivo pathologic mineralization, wherein the surface coating comprises a precursor of the formula;

3. A biocompatible heart valve comprising:

a stent defining a blood flow path; and

a plurality of polymeric leaflets having a surface coating to provide resistance to in vivo pathologic thrombus formation and in vivo pathologic mineralization, wherein the surface coating comprises a precursor selected from the group consisting of;

and derivatives of (II) and (III).